DXCM Dexcom CGM: Long-Term Debt to Capital Coefficient

DexCom, Inc. (DXCM) concentrates its production capacities in Mexico and the US, where it develops vital devices for diabetics. The company relies on external electronics suppliers while maintaining internal control over software and assembly. This price chart illustrates the 0.49 metric for the CGM systems leader, whose patents and FDA approval ensure stable revenue through unique sensors.

The DexCom, Inc. (DXCM) model relies on high-tech glucose monitoring, which is currently facing pricing pressure and demand risks driven by new weight-loss drugs. By analyzing the level of long-term debt-to-equity, an investor assesses the proportion of loans with a maturity exceeding one year within the capitalization structure, which helps determine the company's financial resilience to market shocks or the degree of its conservatism in expanding capacity.